Gelifex

Gelifex is a clinical-stage regenerative medicine company specializing in the development of injectable hydrogel treatments for degenerative disc disease. The company's lead technology is designed to replace or augment the nucleus pulposus, the jelly-like substance in the center of spinal discs, to restore mechanical function and alleviate chronic back pain. By providing a minimally invasive alternative to spinal fusion or total disc replacement, Gelifex aims to transform the standard of care for spinal degeneration. The proprietary hydrogel scaffold mimics the biomechanical properties of natural spinal tissue, promoting structural integrity. In 2021, the company was acquired by Eli Lilly to enhance its portfolio of non-opioid pain therapies and regenerative medicine. This acquisition reflects a strategic move to address the high unmet need in chronic low back pain management.